Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India - A systematic screening intervention
- PMID: 29933863
- DOI: 10.1016/j.ijtb.2018.02.004
Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India - A systematic screening intervention
Abstract
Background: India has the world's highest estimated burden of multi-drug-resistant tuberculosis (MDR-TB). While prevalence of MDR-TB is known to be 2-3% among new TB patients and 12-17% in previously treated patients, programmatic information on the extent of transmission of TB and MDR-TB among household contacts of known MDR-TB patients is scarce. Systematic screening of household contacts of all MDR-TB patients on treatment was implemented as an intervention in the states of Andhra Pradesh and Telangana states of India. We undertook this prospective interventional study to measure the extent of TB symptoms developed among the household contacts of the known MDR-TB patients treated under Revised National TB Control Programme (RNTCP). The extent of rifampicin sensitive or resistance TB, bacteriologically confirmed using Xpert MTB-RIF, was examined among the symptomatic household contacts.
Methods: All MDR-TB patients registered and on treatment under RNTCP between July 2011 and Sep 2013 in Andhra Pradesh and Telangana States were selected for the study. They were contacted through home visit by the trained RNTCP teams during 11th Dec 2013 and 7th Jan 2014. All household contacts of MDR-TB patients were screened once for TB symptoms such as cough, fever, weight loss, night sweats, and haemoptysis and extra pulmonary site specific symptoms if any. If found symptomatic, two sputum specimen were collected (spot-morning) from each of the contact and transported for testing on Xpert MTB-RIF for detection of pulmonary TB with or without RR-TB.
Results: A total of 1750 MDR-TB patients were registered between July 2011 and Sep 2013. Of these, 1602 (91.5%) MDR-TB patients were included in the study. A total of 4858 household contacts of these 1602 patients were identified with an average of 3 contacts per MDR-TB patient. Of these, after excluding 87 (1.8%) contacts with past history of diagnosis and/or treatment for TB, 4771 (98.2%) contacts were screened for current signs and symptoms suggestive of TB. Their mean age was 28.5 years and 2151 (45%) were females. Of the 4771 contacts screened, 793 (16.6%) had at least one of the symptoms suggestive of TB of whom 781 (98.5%) had two sputum specimen transported and tested on Xpert MTB-Rif. Specimen could not be collected during the study period in 12 symptomatic patients including 4 with symptoms of extra pulmonary TB. Among 781 symptomatic contacts examined, 34 (4.4%) were bacteriologically confirmed with TB and 15 (44%) also had Rif resistance (RR).
Conclusions: High extent of TB, particularly RR-TB was observed among household contacts of known MDR-TB patients with symptom screening and early diagnosis using Xpert-MTB-Rif. Regular systematic active screening for TB and MDR-TB among this highly vulnerable group using Xpert-MTB-Rif is useful in India for early diagnosis among close contacts of known MDR-TB patients.
Keywords: Contact screening; Drug resistant TB; Tuberculosis.
Copyright © 2018 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Low prevalence of MDR-TB in Lao PDR: results from the first national anti-tuberculosis drug resistance survey.Trop Med Int Health. 2019 Apr;24(4):421-431. doi: 10.1111/tmi.13205. Epub 2019 Jan 31. Trop Med Int Health. 2019. PMID: 30663180
-
Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms.Cochrane Database Syst Rev. 2021 Mar 23;3(3):CD013694. doi: 10.1002/14651858.CD013694.pub2. Cochrane Database Syst Rev. 2021. PMID: 33755189 Free PMC article.
-
Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study.Ann Palliat Med. 2020 Mar;9(2):239-246. doi: 10.21037/apm.2020.02.17. Epub 2020 Mar 17. Ann Palliat Med. 2020. PMID: 32233619
-
Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.Clin Infect Dis. 2019 Sep 27;69(8):1278-1287. doi: 10.1093/cid/ciy1105. Clin Infect Dis. 2019. PMID: 30759187 Free PMC article.
-
Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children.Cochrane Database Syst Rev. 2020 Aug 27;8(8):CD013359. doi: 10.1002/14651858.CD013359.pub2. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2022 Sep 6;9:CD013359. doi: 10.1002/14651858.CD013359.pub3. PMID: 32853411 Free PMC article. Updated.
Cited by
-
A systematic review and meta-analysis of active case finding for tuberculosis in India.Lancet Reg Health Southeast Asia. 2022 Sep 17;7:100076. doi: 10.1016/j.lansea.2022.100076. eCollection 2022 Dec. Lancet Reg Health Southeast Asia. 2022. PMID: 37383930 Free PMC article.
-
Drug-Resistant Tuberculosis Case-Finding Strategies: Scoping Review.JMIR Public Health Surveill. 2024 Jun 26;10:e46137. doi: 10.2196/46137. JMIR Public Health Surveill. 2024. PMID: 38924777 Free PMC article.
-
Prospective 1-year follow-up study of all cured, new sputum smear positive tuberculosis patients under the Revised National Tuberculosis Control Program in Hyderabad, Telangana State, India.Lung India. 2019 Nov-Dec;36(6):519-524. doi: 10.4103/lungindia.lungindia_143_19. Lung India. 2019. PMID: 31670300 Free PMC article.
-
Performance of algorithms for tuberculosis active case finding in underserved high-prevalence settings in Cambodia: a cross-sectional study.Glob Health Action. 2019;12(1):1646024. doi: 10.1080/16549716.2019.1646024. Glob Health Action. 2019. PMID: 31500551 Free PMC article.
-
Scaling up investigation and treatment of household contacts of tuberculosis patients in Brazil: a cost-effectiveness and budget impact analysis.Lancet Reg Health Am. 2022 Jan 10;8:100166. doi: 10.1016/j.lana.2021.100166. eCollection 2022 Apr. Lancet Reg Health Am. 2022. PMID: 36778732 Free PMC article.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous